Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in moderately to severely active Crohn's disease
2023-509742-35-00Phase 2Completed
- Sponsor
- Prometheus Biosciences
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of tulisokibart in Crohn's disease, sponsored by Prometheus Biosciences. Primary endpoints: Safety and tolerability and Endoscopic improvement at Week 12. Started Nov 2021; status: completed.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-509742-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509742-35-00.